This message is sent to you by FDA Newswatch

Common Problems and Mistakes in Method Validation in Drug Development Process

Wednesday, 11 July 2018 11:30 AM PDT, 02:30 PM EDT

Training Duration = 60 min                  Sponsored by Online Compliance Panel

Click Here to register $250.00

Click Here to register and receive CD recording $500.00

Validation of test methods is a critical requirement for the drug development process. Testing of drug substance and drug product for quality requires validated methods. In addition, testing samples for PK/PD studies require methods that are consistent, robust, rugged, sensitive, and specific in a variety of matrices.

 Collecting sufficient data prior to validation that can reliably support acceptance require is a frequent issue. Setting appropriate acceptance criteria based on data from final development and qualification is important for assay performance in the validation.

This webinar will address issues that arise during development and validation that lead to failure and rework. The webinar also includes approaches to validation that can prevent failure and increase successful completion of validation.

Learning Objectives:

  • Why method development is critical for a good method validation
  • Importance of understanding trends and outliers
  • Appropriate handling and setting of specifications for reagents and samples
  • Importance of pre-validation (qualification) data
  • Implementing good training procedures
  • Defining the validation process
  • Learning from failures

Why Should You Attend:

Validation rework is costly and impacts timelines negatively. Properly preparing for validation contributes to successful, on time completion of method validations. This webinar provides information that will assist attendees with identifying and correcting common issues that may arise during validation of methods required in drug development.

Issues revolving around lack of supporting data for validation acceptance criteria, lack of analyst training, and not testing specific parameters during development will be addressed. Attendees should gain knowledge to help resolve potential issues that may arise during validation.

Areas Covered

  • Defining the method selected for development
  • Certifying the reference standard
  • Setting appropriate limits for reagents
  • Reagent supply and sample handling
  • Testing robustness/ruggedness/selectivity/specificity prior to validation
  • Analyst training
  • Peer review of the test method
  • Validation protocol and templates
  • Preplanning
  • Documentation of deviations and failures


Gwendolyn Wise-Blackman is a successful scientist/manager with increasing accountability for scientific expertise and budget in the pharmaceutical industry, including managing multiple projects. She has working knowledge of FDA/ICH GLP and GMP guidelines and has proven experience with cell-based potency assays, Cell-based neutralization assays, PK and immunogenicity ELISA used to support bioprocess techniques for large molecule therapeutics.

Ms. Wise-Blackman also holds Research & Development expertise in High Throughput Screening, 7-transmembrane receptor binding assays, cell-based assays, cell culture, and ELISA. Ms. Wise-Blackman is gifted with excellent presentation skills as evidenced by numerous scientific speaking engagements and working knowledge of PMP principles. She was an invited lecturer for IBC and IVT conferences, 1999-2008.